Arizona Tribune - Federal Legal Marijuana? MMJ's Billion Dollar Trajectory: We're Not Selling Marijuana, We're Capturing a Market

MMJ International Holdings Is Betting on Medicine, Not Marijuana

Is Pharmaceutical Grade Cannabis Aiming for the Next Blockbuster?

Duane Boise, MMJ's CEO is banking on it. Backed by $10M+ in investment, vertically integrated cultivation and lab operations, and a patient-first mission, MMJ International Holdings is positioned to follow in the footsteps of Epidiolex and Marinol-cannabis derived drugs that now generate hundreds of millions annually.

WASHINGTON, D.C. / ACCESS Newswire / September 14, 2025 / In an industry dominated by recreational sales and wellness trends, MMJ International Holdings is pioneering a pharmaceutical-first approach to cannabinoid therapeutics. Led by CEO Duane Boise, the company is developing FDA-regulated, plant-derived drugs targeting rare neurological disorders and chronic conditions. With two Investigational New Drug (IND) applications filed with the FDA and Orphan Drug Designation for its Huntington's disease treatment, MMJ represents a major shift toward science driven cannabinoid medicine. Its strategy leverages the full therapeutic potential of cannabis within the FDA's gold-standard pharmaceutical framework-opening the door to billion-dollar markets while addressing critical unmet patient needs.

"MMJ International Holdings Is Betting on Medicine, Not Marijuana" Duane Boise CEO

The Pharmaceutical Approach to Cannabis Medicine

Beyond Dispensaries: Building Real Medicine

Unlike the fragmented dispensary model, MMJ is developing prescription-ready, pharmaceutical-grade softgel capsules. Its flagship products:

• MMJ-001: for Multiple Sclerosis

• MMJ-002: for Huntington's Disease (Orphan Designation granted)

These capsules are derived from proprietary cannabis cultivars, optimized to deliver balanced THC and CBD combinations. Each dose is standardized for consistency, potency, and bioavailability-qualities nearly impossible to achieve in retail cannabis.

"Our mission is to deliver cannabis as real medicine," says lead chemist Dr. Elio Mariani, who emphasizes preserving the entourage effect while meeting FDA requirements for dosing and safety.

Vertical Integration for Quality

Through its subsidiaries, MMJ maintains strict quality control from seed to softgel:

• MMJ BioPharma Cultivation - grows proprietary cannabis strains optimized for pharmaceutical use.

• MMJ BioPharma Labs - a DEA Schedule I licensed analytical lab manufacturing formulations under GMP standards.

This vertical model ensures consistency and regulatory compliance at every stage-critical factors for FDA approval and market acceptance.

Regulatory Strategy and Milestones : Navigating the FDA Pathway

MMJ has advanced through the challenging FDA drug development process:

• Two INDs filed (MS & Huntington's Disease)

• Orphan Drug Designation for Huntington's

• Successful preclinical work with leading U.S. neurologists

Why Orphan Status Matters

The FDA's Orphan Drug Designation for Huntington's gives MMJ:

• 7 years of U.S. market exclusivity

• Tax credits for clinical costs

• Waived FDA fees (~$2.5M per filing)

• Accelerated review pathways

This advantage positions MMJ to capture a first-mover monopoly in a devastating disease with no cure.

Market Potential and Opportunity: Following a Proven Trajectory

Cannabis-derived pharmaceuticals are proven blockbusters:

• Marinol (dronabinol) - FDA-approved synthetic THC (~$250M annual sales)

• Epidiolex (cannabidiol) - FDA-approved CBD drug, nearing $1B+ annual sales with a patient population of just ~100,000

"If Epidiolex can approach a billion dollars a year with such a small population, imagine the potential for MMJ's capsules treating Multiple Sclerosis, Huntington's, and eventually chronic pain," says Boise.

Expanding Beyond Orphan Diseases

• Huntington's Disease - tens of thousands of patients, no effective treatments

• Multiple Sclerosis - a multibillion-dollar global market

• Chronic Pain - a $20B+ annual U.S. market, desperately seeking non-opioid alternatives

Given the opioid crisis-125M prescriptions in 2023 and 80,000 overdose deaths last year-safe cannabinoid-based pain therapies could transform care and capture significant market share.

Leadership and Motivation

Boise's mission is rooted in personal experience. His father served 40 years in law enforcement, and both parents battled Parkinson's disease. "That taught me the urgency of building legitimate, science driven treatments," he says.

To date, MMJ has invested over $10 million to bring this vision forward, navigating what Boise calls a "Kafkaesque trap" of U.S. cannabis regulations. Despite roadblocks, he has kept MMJ firmly aligned with FDA rules, distinguishing the company from recreational operators.

"If you're serious about medicine, you follow the science-not the hype," Boise notes.

Industry Landscape and Differentiation MMJ has carved out a unique position by:

• Developing full-spectrum, natural cannabinoid formulations

• Delivering via softgel capsules for reproducibility

• Pursuing FDA drug approval, unlike supplement or state dispensary models

Compared with synthetic single-molecule THC (Marinol) or failed attempts like nabiximols, MMJ's natural, standardized softgels represent a new class of medicine with stronger clinical promise.

Outlook: From Quiet Player to Market Leader

Regulatory Tailwinds

• DEA rescheduling to Schedule III could ease barriers

• Trump administration drug development policy changes

• Increasing FDA guidance supports botanical drug pathways

Growth Opportunities

• Advancement of MMJ-002 into Phase II trials

• Expansion of pipeline into pain and other neurological indications

• International partnerships for global distribution

MMJ Redefining Cannabis Medicine

MMJ International Holdings is not chasing hype-it's building a pharmaceutical legacy. With orphan designation secured, INDs filed, and a pipeline designed for blockbuster potential, the company represents the quiet revolution in medical cannabis: transforming cannabinoids from uncertain dispensary products into standardized, FDA-approved medicines.

"MMJ didn't set out to sell marijuana," Boise emphasizes. "We set out to make real medicine-and that's what we've built."

MMJ is represented by attorney Megan Sheehan.

CONTACT:
Madison Hisey
[email protected]
203-231-85832

SOURCE: MMJ International Holdings

View the original press release on ACCESS Newswire

W.Nelson--AT